{'fraction_non_alphanumeric': 0.04028197381671702, 'fraction_numerical': 0.022155085599194362, 'mean_word_length': 5.371794871794871, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cytokine Gene Modification of Bladder Cancer Cells for the Establishment of Bladder Cancer Vaccine

A bladder tumor vaccine in mouse models was established by introducing interleukin–2 (IL–2) gene into mouse bladder cancer cells (MBT–2). Mice injected with non–modified MBT–2 cells did not reject subsequent challenge of MBT–2 cells. Mice injected with IL–2–gene–modified MBT–2 cells (MBT–2/IL–2) rejected subsequent challenge of unmodified MBT–2 cells but not 38C13 cells, which have the same genetic background but different antigenicity. According to these results, an injection of MBT–2/II.–2 can establish specific immunity against parental MBT–2 cells in mice, which is also demonstrated by cytotoxic T lymphocytes assay. Vaccinations with MBT–2/IL–2 cured 60% of bladder cancer which had been pre–established in mice. These results suggest that tumor cells genetically modified with IL–2 gene can act as a tumor vaccine which is expected to be a new method for immunotherapy of cancers.